Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT.
Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype of peripheral T-cell lymphomas with a poor prognosis. Autologous stem cell transplantation (ASCT) was retrospectively evaluated as a consolidation or salvage strategy for EATL. The analysis included 44 patients who received ASCT for EATL between 2000 and 2010. Thirty-one patients (70%) were in first complete or partial remission at the time of the ASCT. With a median follow-up of 46 months, relapse incidence, progression-free survival, and overall survival were 39%, 54%, and 59% at 4 years, respectively, with only one relapse occurring beyond 18 months posttransplant. There was a trend for better survival in patients transplanted in first complete or partial remission at 4 years (66% vs 36%; P = .062). ASCT is feasible in selected patients with EATL and can yield durable disease control in a significant proportion of the patients.
University of Eastern Finland/Clinical Medicine and Department of Medicine, Kuopio University Hospital, Kuopio, Finland. esa.jantunen@kuh.fi
Esa
E
Jantunen
Ariane
A
Boumendil
Herve
H
Finel
Jian-Jian
JJ
Luan
Peter
P
Johnson
Alessandro
A
Rambaldi
Andrew
A
Haynes
Michel A
MA
Duchosal
Wolfgang
W
Bethge
Pierre
P
Biron
Kristina
K
Carlson
Charles
C
Craddock
Claudius
C
Rudin
Jurgen
J
Finke
Gilles
G
Salles
Frank
F
Kroschinsky
Anna
A
Sureda
Peter
P
Dreger
D000328:Adult; D000368:Aged; D058527:Enteropathy-Associated T-Cell Lymphoma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D005260:Female; D005858:Germany / Q000453:epidemiology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000458:organization & administration; D008875:Middle Aged; D012189:Retrospective Studies; D012955:Societies, Medical; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome